Document is current
Any future updates will be listed below
-
Authors
Hakovirta, Harri
Jalkanen, Juho
Saimanen, Eija
Kukkonen, Tiia
Romsi, Pekka
Suominen, Velipekka
Vikatmaa, Leena
Valtonen, Mika
Karvonen, Matti K.
Venermo, Maarit
,
Hakovirta, Harri
Jalkanen, Juho
Saimanen, Eija
Kukkonen, Tiia
Romsi, Pekka
Suominen, Velipekka
Vikatmaa, Leena
Valtonen, Mika
Karvonen, Matti K.
Venermo, Maarit
Nikulainen, Veikko
Wickström, Jan-Erik
Kaskinoro, Kimmo
Vikatmaa, Pirkka
Kantonen, Ilkka
Tulamo, Riikka
Uurto, Ilkka
Vakhitov, Damir
Pokela, Matti
Ilo, Arjaleena
Mäenpää, Mika
Frant, Miikka
Pihlaja, Toni
Koskenkari, Juha
Virkkunen, Jyrki
Laru-Sompa, Raili
Pulkkinen, Anni
Savolainen, Hannu
Mäkelä, Antti
Hovilehto, Seppo
Aavik, Asser
Lieberg, Jüri
Rajaste, Geidi
Kals, Jaak
Metsa, Andrus
Ellervee, Toomas
Järve, Heli
Sarapuu, Silver
Tamme, Kadri
Velicka, Linas
Laukaitis, Martynas
Lenkutis, Tadas
Misonis, Nerijus
Asekiene, Ingrida
Skrebunas, Arminas
Kekstas, Gintautas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03119701 at ClinicalTrials.govDocuments that mention this clinical trial
Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study
https://doi.org/10.1038/s41598-022-05771-1
-
Funding
Funding for this research was provided by:
This study was sponsored by Faron Pharmaceuticals Ltd.
- License Information
-
More Information
Article History
Received: 23 September 2021
Accepted: 18 January 2022
First Online: 3 February 2022
Competing interests
: Dr Jalkanen and Karvonen own stock and are employed by Faron Pharmaceuticals Ltd. Other authors declare no competing interests.
